

## Contents

**Preface** XV  
**List of Contributors** XVII

### Part I Introduction 1

**1 Pathogenesis of Atherosclerosis** 3  
*Sarah Jane George and Cressida Lyon*

1.1 Epidemiology of Coronary Heart Disease 3  
 1.2 Risk Factors 3  
 1.3 Atherosclerosis 5  
 1.4 Initiation of Plaque Formation–Endothelial Dysfunction 9  
 1.5 Inflammation 10  
 1.6 Foam Cell Formation 12  
 1.7 Vascular Smooth Muscle Cell Migration and Proliferation 13  
 1.8 Plaque Rupture and Thrombus Formation 14  
 References 16

### Part II PRO-Inflammatory Factors 21

**2 Chemokines and Atherosclerosis: A Critical Assessment of Therapeutic Targets** 23  
*Gemma E. White, Keith M. Channon, and David R. Greaves*

2.1 Introduction 23  
 2.1.1 Chemokines 23  
 2.1.2 Chemokine Receptors 24  
 2.1.3 Chemokine Functions 24  
 2.2 Key Chemokine Functions in Atherogenesis 25  
 2.3 Experimental Evidence for the Role of Chemokines in Atherosclerosis 27  
 2.3.1 CCL2 Acting via CCR2 28

2.3.2	CCL3, 4, 5 Acting via CCR1 and CCR5	28
2.3.3	CXCL9,10, 11 Acting via CXCR3	29
2.3.4	CXCL1/CXCL8 Acting via CXCR2	30
2.3.5	CX <sub>3</sub> CL1 Acting via CX <sub>3</sub> CR1	30
2.4	Strategies for Targeting Chemokines in Atherosclerosis	31
2.4.1	Neutralizing Antibodies	31
2.4.2	Small Molecule Inhibitors	32
2.4.3	Mutant Chemokines	33
2.4.3.1	N-Terminal Chemokine Mutants	33
2.4.3.2	Disruption of Oligomerization	34
2.4.4	Broad-Spectrum Chemokine Blockade	34
2.5	Conclusions and Future Clinical Prospects for Chemokine Targeting	35
	References	37
<b>3</b>	<b>Adhesion Molecules and Atherosclerosis</b>	<b>43</b>
	<i>Huan Wang and Yuqing Huo</i>	
3.1	The Leukocyte Adhesion Cascade in Atherosclerosis	43
3.2	Background on Adhesion Molecules	44
3.2.1	Selectins and Their Ligands	44
3.2.2	Immunoglobulin Superfamily and its Counterreceptors	45
3.3	Adhesion Molecules and Risk Factors of Atherosclerosis	46
3.4	Adhesion Molecule Expression and Function in Atherosclerosis	48
3.5	Atherogenesis of Adhesion Molecules in Animal Models	50
3.6	Adhesion Molecules as Clinical Predictors of Atherosclerotic Diseases	53
3.7	Adhesion Molecules as Therapeutic Targets	54
	References	55
<b>4</b>	<b>Cytokines and Atherosclerosis</b>	<b>63</b>
	<i>Alain Tedgui, Hafid Ait-Oufella, and Ziad Mallat</i>	
4.1	Introduction	63
4.2	The Cytokine Network	64
4.3	Biological Effects of Cytokines in Atherosclerosis	65
4.4	Cytokine Expression in Human Atherosclerotic Plaques	68
4.5	Effect of Cytokines on Experimental Atherosclerosis	69
4.5.1	TNF- $\alpha$ and Structurally Related Cytokines	69
4.5.2	IL-1 Cytokine Family	69
4.5.3	Inflammasome	71
4.5.4	IL-6 Family	71
4.5.5	IL-12 Family	72
4.5.6	IL-19/IL-20	74
4.5.7	IFN- $\gamma$ and Th1-Related Cytokines	75
4.5.8	IL-4/IL-5 and Th2-Related Cytokines	75

4.5.9	TGF $\beta$ /IL-10 and T <sub>reg</sub> -Related Cytokines	76
4.6	Conclusion	77
	References	78
<b>5</b>	<b>Toll-Like Receptors in Atherosclerosis</b>	<b>85</b>
	<i>Zhong-qun Yan, Kristina Edfeldt, and Anna M. Lundberg</i>	
5.1	Introduction	85
5.2	Toll-Like Receptors, Molecular Pattern Recognition, and Signal Transduction Pathways	85
5.3	TLR Expression Patterns in Atherosclerosis	90
5.4	TLRs in the Pathogenesis of Atherosclerosis	90
5.4.1	TLRs on Vascular Cells— <i>In Vitro</i> Studies	90
5.4.2	Genetic Variants of TLRs and Their Association with CAD	91
5.4.3	The Role of TLRs in Atherosclerosis—Experimental Models	92
5.5	Exogenous TLR Ligands—Infections in Atherosclerosis	93
5.6	Endogenous TLR Ligands—Triggering Inflammation in the Absence of Exogenous Infectious Stimuli	93
5.7	Summary	94
	Acknowledgments	95
	References	95
<b>6</b>	<b>PPAR-Based Therapies for the Management of Atherosclerosis</b>	<b>105</b>
	<i>Florence Gizard and Inés Pineda-Torra</i>	
6.1	PPARs: Nuclear Receptors as Pleiotropic Transcriptional Regulators	105
6.2	PPAR $\alpha$	107
6.2.1	PPAR $\alpha$ in Metabolic Control	107
6.2.2	PPAR $\alpha$ in the Vasculature	108
6.2.2.1	Vascular Endothelium	108
6.2.2.2	Monocytes/Macrophages/T Lymphocytes	108
6.2.2.3	SMCs	109
6.2.3	PPAR $\alpha$ in Animal Models of Atherosclerosis and Associated Vascular Complications	110
6.2.4	PPAR $\alpha$ in Cardiovascular Clinical Trials	112
6.2.5	Perspectives for PPAR $\alpha$ -Based Therapies	114
6.3	PPAR $\delta$	114
6.3.1	PPAR $\delta$ in Metabolic Control	114
6.3.1.1	PPAR $\delta$ and Metabolic Syndrome	115
6.3.2	PPAR $\delta$ in the Vasculature	116
6.3.2.1	Macrophage Metabolism and Inflammation	116
6.3.3	PPAR $\delta$ in the Alternative Activation of Macrophages	117
6.3.4	PPAR $\delta$ in Atherosclerosis	118
6.3.5	PPAR $\delta$ in Human Studies	119
6.3.6	Perspectives for PPAR $\delta$ -Based Therapies	120
6.4	PPAR $\gamma$	120

6.4.1	PPAR $\gamma$ Actions in the Vasculature	121
6.4.1.1	Vascular Endothelium	121
6.4.1.2	Monocytes/Macrophages/T Lymphocytes	122
6.4.1.3	SMCs	123
6.4.2	PPAR $\gamma$ in Animal Models of Atherosclerosis and Associated Vascular Complications	124
6.4.3	PPAR $\gamma$ in Human Cardiovascular Clinical Diseases	125
6.5	PPARs: Conclusion and Perspectives	127
	Acknowledgment	128
	References	128
<b>7</b>	<b>Pentraxins in Vascular Pathology: The Role of PTX3</b>	<b>137</b>
	<i>Alberto Mantovani, Cecilia Garlanda, Barbara Bottazzi, Fabiola Molla, and Roberto Latini</i>	
7.1	Introduction	137
7.2	The Pentraxin Superfamily	137
7.3	Gene and Protein Production and Regulation	138
7.4	Role of PTX3 in Innate Immunity and Inflammation	141
7.5	PTX3 in Models of Vascular Pathology	144
7.6	PTX3 as Marker of Vascular Pathology	145
7.7	Concluding Remarks	148
	Acknowledgment	148
	References	148
	<b>Part III Proteases</b>	<b>155</b>
<b>8</b>	<b>Metalloproteinases, the Endothelium, and Atherosclerosis</b>	<b>157</b>
	<i>Stephen J. White, and Andrew C. Newby</i>	
8.1	Introduction and Scope of this Review	157
8.2	General Comments on the Role of MMP Production from ECs in Atherosclerosis	159
8.3	Endothelial Responses to Laminar and Oscillatory Shear Stress	162
8.4	Response to Step Changes in Shear Stress	163
8.5	Response to Cyclic Strain	164
8.6	Response to Inflammatory Mediators	164
8.7	Response to Angiogenic Signals	165
8.8	Signaling by MMPs	165
8.9	Conclusions	166
	Acknowledgments	167
	References	168
<b>9</b>	<b>Cathepsins in Atherosclerosis</b>	<b>173</b>
	<i>Lili Bai, Esther Lutgens, and Sylvia Heeneman</i>	
9.1	Introduction	173
9.2	Synthesis and Activity	173

9.3	Regulation	174
9.4	Cathepsins in (Patho)physiological Tissue Remodeling	174
9.5	Cathepsins in Atherosclerosis	175
9.5.1	Expression of Cathepsins in Human Atherosclerosis	175
9.5.2	The Role of Cathepsins in Atherogenesis: Lessons Learned from Animal Models	177
9.5.3	Cathepsins in Atherosclerosis: Potential Mechanisms	177
9.5.3.1	Cathepsins are Regulated by Shear Stress	177
9.5.3.2	Cathepsins Mediate Leukocyte and SMC Migration	178
9.5.3.3	Cathepsin-Induced ECM Degradation in Atherosclerosis	179
9.5.3.4	Cathepsin-Mediated Neovascularization	180
9.5.3.5	Cathepsins Mediate Inflammation	180
9.5.3.6	Apoptosis	182
9.5.3.7	Lipid Metabolism	182
9.5.3.8	Thrombus Formation	183
9.5.4	Cathepsins in Plaque Instability	184
9.6	Therapeutic Potential	184
9.7	Conclusions	184
	References	185
<b>10</b>	<b>The Plasmin System and Atherosclerosis</b>	<b>193</b>
	<i>Christopher L. Jackson, and Kevin G.S. Carson</i>	
10.1	Introduction	193
10.2	Components of the Plasmin System	193
10.2.1	Tissue-Type Plasminogen Activator	193
10.2.2	Urokinase-Type Plasminogen Activator	194
10.2.3	uPA Receptor	194
10.2.4	Plasminogen	195
10.2.5	Plasmin	195
10.2.6	Plasminogen Activator Inhibitor-1	195
10.2.7	Plasminogen Activator Inhibitor-2	195
10.2.8	Endogenous Plasmin Inhibitors	195
10.2.9	Thrombin-Activatable Fibrinolysis Inhibitor	196
10.3	Involvement of the Plasmin System in Atherosclerosis	196
10.3.1	Human Gene Polymorphisms	196
10.3.2	Clinical Association Studies	197
10.3.3	Studies in Mice	197
10.3.3.1	Plasminogen	197
10.3.3.2	tPA	199
10.3.3.3	uPA	199
10.3.3.4	PAI-1	201
10.4	Summary and Conclusions	202
	References	203

<b>11</b>	<b>Mast Cell Proteases and Atherosclerosis</b>	<b>207</b>
	<i>Petri T. Kovanen</i>	
11.1	Introduction	207
11.2	Mast Cell Progenitors Enter the Arterial Intima and Differentiate into Mature Mast Cells Filled with Protease-Containing Cytoplasmic Secretory Granules	207
11.3	Mast Cells in Fatty Streak Lesions and Mechanisms by Which Their Proteases May Contribute to Foam Cell Formation	209
11.3.1	Proteolytic Degradation of LDL Particles by Mast Cell Chymase	209
11.3.2	Proteolytic Degradation of HDL Particles by Mast Cell Chymase and Tryptase	212
11.4	Mast Cells in Advanced Coronary Atherosclerotic Plaques, and Mechanisms by Which They May Promote Plaque Rupture and Erosion	215
11.4.1	Potential Mechanisms by Which Mast Cell Proteases Induce Loss of Extracellular Matrix and Smooth Muscle Cells in Atherosclerotic Plaques	216
11.4.2	Potential Mechanisms by Which Mast Cell Induce Death or Detachment of Endothelial Cells in Atherosclerotic Plaques	218
11.5	Mast Cells around Coronary Plaque Neovessels—Additional Mechanisms by Which Mast Cell Proteases May Promote Plaque Vulnerability	220
11.6	Genetically and Pharmacologically Manipulated Mice—An Opportunity to Rigorously Test the Role of Mast Cell Proteases in Atherogenesis	222
11.7	Epilogue	223
	Acknowledgments	224
	References	224

**Part IV Hyperlipidemia 229**

<b>12</b>	<b>Macrophage Foam Cell Formation: The Pathways to Cholesterol Engorgement</b>	<b>231</b>
	<i>Kathryn J. Moore Katey Rayner</i>	
12.1	Introduction	231
12.2	ox-LDL, the Scavenger Receptors and Foam Cell Formation	233
12.2.1	Scavenger Receptor A	233
12.2.2	The Class B Scavenger Receptor CD36	235
12.2.3	Lectin-Like ox-LDL Receptor LOX-1	237
12.2.4	CXCL16/SR-PSOX: A Scavenger Receptor and a Chemokine	237
12.2.5	New Insights into Scavenger Receptor Function in Atherosclerosis	238
12.2.5.1	Cell Migration	238
12.2.5.2	Apoptosis	238

- 12.2.5.3 Novel Ligands 239
- 12.2.5.4 Other Mechanisms of SRs in Atherosclerosis 239
- 12.3 Enzymatic Modifications of LDL Leading to Foam Cell Formation 240
- 12.4 Native Lipoprotein Receptors and Foam Cell Formation 242
- 12.5 Receptor-Independent Macrophage Cholesterol Accumulation 243
- 12.6 Macrophage Cholesterol Efflux Pathways 244
- 12.7 Summary 245
- References 246

## Part V Oxidative Stress 255

- 13 NADPH Oxidase and Atherosclerosis 257**  
*Jamie Y. Jeremy, Saima Muzaffar, Carina Mill and Nilima Shukla*
- 13.1 Introduction 257
- 13.2 Biology of NADPH Oxidases 257
- 13.3 Studies in Human Tissues and Knockout Mice 259
- 13.4 Apoptosis 261
- 13.5 Cell Proliferation and Migration 262
- 13.6 Nitric Oxide 263
- 13.7 Eicosanoids 265
- 13.8 Angiogenesis and Neovascularization 268
- 13.9 MMPs, Wnt- $\beta$  Catenin and Forkhead Box (FOX) Signaling Pathway 269
- 13.10 Therapeutic Strategies Involving Inhibition of NOX 270
- 13.11 Concluding Remarks 271
- References 271
  
- 14 Uncoupling of Endothelial Nitric Oxide Synthase in Atherosclerosis 275**  
*Colin Cunningham and Keith M. Channon*
- 14.1 Introduction: Nitric Oxide and the Endothelium 275
- 14.2 Production of NO in the Endothelium 275
- 14.2.1 NOS Structure and Function 276
- 14.2.2 Requirement of BH<sub>4</sub> as a Cofactor for NOS 278
- 14.2.3 BH<sub>4</sub> Synthesis 278
- 14.3 NOS Uncoupling 278
- 14.3.1 eNOS Uncoupling 279
- 14.3.1.1 Studies of Purified eNOS Enzyme 279
- 14.3.1.2 Studies of Pharmacological BH<sub>4</sub> Supplementation and Depletion 280
- 14.3.1.3 Alteration of BH<sub>4</sub> Levels via Genetic Manipulation of GTP-CH 280
- 14.3.1.4 Paradoxical Findings in Chronic eNOS Overexpression 281
- 14.3.2 Oxidation of Tetrahydrobiopterin: The Role of Peroxynitrite 282

14.3.3	The Ratio of Reduced to Oxidized Bioterins in eNOS Regulation	283
14.4	eNOS Uncoupling in Experimental Disease Models	283
14.4.1	Diabetes and Insulin Resistance	286
14.4.2	Hypertension	286
14.4.3	Hypercholesterolemia	287
14.5	Human Studies	288
14.5.1	Studies of Isolated Blood Vessels	288
14.5.2	Clinical Studies	289
14.6	Conclusion	291
	Acknowledgments	292
	References	292

## **15 Heme Oxygenase-1 and Atherosclerosis 301**

*Justin C. Mason and Faisal Ali*

15.1	Background	301
15.2	Heme Oxygenases	301
15.3	Epidemiology	303
15.3.1	HO-1 Promoter Polymorphisms	303
15.4	Expression of HO-1 in Atherosclerotic Plaques	304
15.5	Genetic Modification of HO-1	305
15.6	Protection Against Ischemia-Reperfusion Injury	306
15.7	How Does HO-1 Exert Its Effects	307
15.7.1	Carbon Monoxide	307
15.7.2	Bilirubin and Biliverdin	308
15.7.3	Ferritin	308
15.7.4	HO-1 and the Activation of the Complement Pathway	309
15.7.5	Modulation of Cell Proliferation and Angiogenesis	309
15.8	Regulation of HO-1 Expression and Activity	311
15.8.1	Nuclear Factor Erythroid 2–Related Factor (Nrf2)	311
15.8.2	Shear Stress	311
15.9	Therapeutic Manipulation of HO-1	312
15.9.1	Lipid-Lowering Drugs	312
15.9.2	Anti-Inflammatory and Immunomodulatory Drugs	314
15.10	Stem cell and Gene Therapy	315
15.11	Conclusions	316
	References	317

## **Part VI Cell Growth and Phenotype 325**

### **16 Phenotypic Heterogeneity of Smooth Muscle Cells—Implications for Atherosclerosis 327**

*Matteo Coen and Marie-Luce Bochaton-Piallat*

16.1	The Concept of Smooth Muscle Cell Heterogeneity	327
16.2	<i>In Vivo</i> Establishment of SMC Phenotypic Switch	328

16.2.1	Morphological Features	328
16.2.2	Cytoskeletal Features	328
16.3	<i>In Vitro</i> Establishment of SMC Phenotypic Switch	330
16.3.1	Identification of SMC Subpopulations in Animal Models	330
16.3.2	Identification of SMC Subpopulations in Humans	331
16.3.3	Biological Features of SMC Subpopulations	332
16.3.3.1	Proliferative Activity and Apoptosis	332
16.3.3.2	Migratory and Proteolytic Activities	332
16.3.3.3	Cytoskeletal Features	332
16.3.3.4	Other Features	333
16.3.4	Biomarkers of SMC Subpopulations	333
16.4	Factors Influencing SMC Phenotypic Switch	335
16.5	Conclusions and Perspectives	336
	Acknowledgments	337
	References	337
<b>17</b>	<b>Platelets: Their Role in Atherogenesis and Thrombosis in Coronary Artery Disease</b>	<b>343</b>
	<i>Matthew T. Harper, Lucy MacCarthy-Morrogh, Matthew L. Jones, Olga Konopatskaya, and Alastair W. Poole</i>	
17.1	Introduction	343
17.2	Platelets	343
17.2.1	Platelet Secretory Organelles	344
17.2.1.1	$\alpha$ -Granules	344
17.2.1.2	Dense Granules	345
17.2.1.3	Lysosomes	345
17.2.1.4	Granule Heterogeneity	347
17.3	Role of Platelets in Atheroprotection	347
17.3.1	Platelets Adhere to Activated Endothelium	347
17.3.1.1	Tethering and Rolling	347
17.3.1.2	Stable Adhesion	348
17.3.2	Consequences of Platelet Adhesion: Endothelial Cell and Platelet Activation, Leukocyte Recruitment, and Monocyte Differentiation	348
17.3.3	Platelet Interactions with Leukocytes	349
17.4	Role of Platelets in Atherothrombosis	351
17.4.1	Plaque Rupture Initiates Coagulation and Exposes Platelet Activators	351
17.4.1.1	Tissue Factor Initiates Coagulation	351
17.4.1.2	Platelets Adhere to Exposed Collagen via Multiple Receptors	351
17.4.1.3	GPVI is the Major Signaling Receptor for Collagen Whereas $\alpha_2\beta_1$ Promotes Firm Adhesion on Collagen	353
17.4.1.4	Activated Platelets Recruit Further Platelets to the Thrombus	353
17.4.1.5	Thrombin is a Potent Platelet Activator	354
17.4.1.6	Inside-Out Activation of $\alpha_{IIb}\beta_3$ is Required for Platelet Aggregation	355

17.4.1.7 Activated Platelets Enhance TF-Mediated Thrombin Generation 355  
 17.5 Mechanisms of Platelet Granule Secretion 356  
 17.5.1 Molecular Regulation of Platelet Exocytosis 356  
 17.6 Conclusion 357  
 References 358

**18 Modulators of Monocyte and Macrophage Phenotypes in Atherosclerosis 365**

*Jason L. Johnson and Nicholas P. Jenkins*

18.1 Introduction 365  
 18.1.1 Origin of Monocyte and Macrophage Populations 365  
 18.1.2 Human Monocyte Heterogeneity 367  
 18.1.2.1 CD14<sup>+</sup>/CD16<sup>-</sup> Monocytes 367  
 18.1.2.2 CD14<sup>+</sup>/CD16<sup>+</sup> Monocytes 367  
 18.1.3 Mouse Monocyte Heterogeneity 370  
 18.1.3.1 CD115<sup>+</sup>/Ly6C<sup>high</sup> Monocytes 370  
 18.1.3.2 CD115<sup>+</sup>/Ly6C<sup>low</sup> Monocytes 370  
 18.1.4 Human Macrophage Heterogeneity 371  
 18.1.4.1 Recruited Macrophages 372  
 18.1.4.2 Resident Macrophages 373  
 18.2 Role of Monocytes/Macrophages in Atherosclerosis 375  
 18.3 Monocyte Polarization and Atherosclerosis 376  
 18.4 Macrophage Polarization and Atherosclerosis 377  
 18.5 Concluding Remarks 380  
 References 381

**Index 387**